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UNDERSTANDING THE ROLE OF KLHL41 INTERACTORS IN NEMALINE 
MYOPATHY 
CAROLINE JIRKA 
ABSTRACT 
 Nemaline Myopathy is a congenital disorder that is characterized by muscle 
weakness and limited mobility. Clinically, Nemaline Myopathy is highly heterogeneous, 
ranging from severe congenital forms with neonatal death to more mild childhood and 
adult onset forms. Mutations in 10 different genes have been linked to Nemaline 
Myopathy in human patients (ACTA1, NEB, TPM3, TPM2, CFL2, TNNT1, LMOD3, 
KBTBD13, KLHL40, and KLHL41). Approximately 75% of Nemaline Myopathy cases 
with a known genetic diagnosis are caused by mutations in structural proteins within the 
thin filaments in skeletal muscle.  It is very difficult to develop therapies that target 
structural proteins and there are no effective, specific therapies for Nemaline Myopathy. 
Recent discovery of mutations in Kelch family genes, which are non-structural genes, 
provide an alternative pathway for developing targeted treatments for Nemaline 
Myopathy.  
 Of particular interest in this study is the protein KLHL41. Mutation of KLHL41 
has shown a clear genotype-phenotype relationship in Nemaline Myopathy with 
frameshift mutations resulting in severe forms and missense mutations resulting in typical 
congenital forms. KLHL41 is found primarily in striated muscle and plays a role in 
protein turnover through the ubiquitin-proteasome pathway. KLHL41 interacts with 
Cullin 3 and serves as a substrate adapter in the E3 ligase complex, the last step in 
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ubiquitination of proteins targeted for degradation by proteasomes. Preliminary studies 
demonstrate that KLHL41 interacts with nebulin, a major structural protein in muscle. 
Mutations in the nebulin gene are implicated in 50% of Nemaline Myopathy cases. 
KLHL41 has also been shown to interact with POMP, a protein that facilitates the 
formation of the 20S proteasome subunit. The proteasome pathway has been shown to be 
impaired in Nemaline Myopathy patients, regardless of genetic mutation. A better 
understanding of how the proteasome pathway becomes disrupted in Nemaline Myopathy 
will contribute to the development of specific targeted therapies.  
 This study sought to understand the significance of KLHL41-protein interactions 
on disease pathology in Nemaline Myopathy. Co-transfection of increasing amounts of 
KLHL41 with constant levels of POMP or a nebulin fragment showed a decrease in 
POMP and nebulin expression, suggesting that KLHL41 is a negative regulator of POMP 
and nebulin.  Co-transfection and immunoprecipitation were also performed to confirm 
the direct interaction between KLHL41 and POMP or nebulin. However, this study could 
not re-confirm a direct physical interaction between KLHL41 and POMP or nebulin 
identified by previous Y2H and HTRF studies.  
As a substrate adapter in the E3 ligase complex, KLHL41 plays an important role 
in protein turnover and disruption of this pathway may contribute to the pathology of 
Nemaline Myopathy. Confirming the role of KLHL41 in the development of Nemaline 
Myopathy is critical to development of future therapeutic strategies. 
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INTRODUCTION 
Congenital Myopathies 
Congenital myopathies are a group of genetic disorders that result in muscle 
weakness at birth or in infancy (“Congenital Myopathy Information Page: National 
Institute of Neurological Disorders and Stroke (NINDS),” n.d.). Congenital myopathies 
occur in 6 in 100,000 live births every year (Wallgren-Pettersson, 1990). Muscle 
weakness found in congenital myopathies can vary from mild to severe which can limit 
mobility, feeding, and breathing in the most severe cases. Congenital myopathies are 
typically myogenic with impairment directly due to a pathological defect originating 
within muscle. (“Congenital Myopathy Information Page: National Institute of 
Neurological Disorders and Stroke (NINDS),” n.d.). There are several distinct types of 
congenital myopathies based on structural abnormalities in myofibers but the most 
common one is Nemaline Myopathy, which is estimated to occur in 1 in 50,000 live 
births (Sanoudou & Beggs, 2001).  
 
Nemaline Myopathy  
Nemaline Myopathy is a heterogeneous group of myopathies characterized by 
muscle weakness and rod-shaped inclusions, called nemaline bodies, in muscle biopsies. 
Nemaline Myopathy was first characterized by Conen et al. (1963) and Shy et al. (1963). 
The major clinical characteristics of Nemaline Myopathy are muscle weakness, 
hypotonia (decreased muscle tone), and depressed or absent reflexes. Hyoptonia results in 
	  2 
floppy infant syndrome. Muscle weakness usually affects the face, neck, and proximal 
muscles, including the shoulder, pelvis, upper arms, and upper legs.  Facial muscle 
weakness leads to development of distinctive facial features such as an elongated face, a 
displaced jaw, and a highly arched palate. Muscle weakness in face and neck muscles can 
lead to problems with speaking and swallowing and may result in the need for a feeding 
tube in some infants. Weakness in respiratory muscles can lead to difficulty breathing, 
the need for respiratory assistance such as a ventilator, and in severe cases death from 
respiratory insufficiency. Infants with Nemaline Myopathy are often slow to attain 
milestones in motor development such as head control and sitting up or standing. As 
infants and children affected with Nemaline Myopathy grow up they often develop 
abnormally fixed joints or curvature of the spine due to restricted movement in diseased 
muscle (North & Ryan, 1993).  
Nemaline myopathies have been classified into six different forms based on 
clinical presentation and age of onset (North & Ryan, 1993). 
 
Severe Congenital: 
The severe congenital form of Nemaline Myopathy accounts for 16% of 
Nemaline Myopathy cases. Patients have extreme muscle weakness and symptoms 
present at birth. Affected infants show little spontaneous movement and have severe 
weakness in respiratory muscles that leads to respiratory failure. Severe congenital 
Nemaline Myopathy results in neonatal death. 
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Intermediate Congenital: 
The intermediate congenital form of Nemaline Myopathy accounts for 20% of 
cases. Affected patients display significant muscle weakness, although less severe than 
the severe form of Nemaline Myopathy. Infants initially display antigravity movement 
and respiratory independence at birth. However, shortly after birth infants fail to reach 
motor movement milestones and often require respiratory support during childhood. 
 
Typical Congenital: 
The typical congenital form of Nemaline Myopathy accounts for 46% of cases. 
Symptoms present at birth or within the first year of life and are less severe than the other 
congenital forms of Nemaline Myopathy. Significant muscle weakness mostly affects the 
proximal muscles and weakness of respiratory muscles is common. Children have 
problems walking, swallowing, and breathing and have delayed motor development. 
Muscle weakness usually does not progress. 
 
Childhood Onset: 
The childhood onset form of Nemaline Myopathy accounts for 13% of cases. 
Patients have normal early motor development and symptoms do not appear until ages 
10-20 years. Those affected experience foot drop and then progressive muscle weakness 
in their legs. 
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Adult Onset: 
The adult onset form of Nemaline Myopathy accounts for 4% of cases. Symptoms 
present between ages 20-50 years and generalized muscle weakness progresses rapidly.  
 
Amish: 
A rare form of Nemaline Myopathy has been found in several related families in 
an Amish community. This is a severe form of Nemaline Myopathy and symptoms 
present shortly after birth. Amish Nemaline Myopathy is associated with a unique set of 
clinical symptoms not seen in other Nemaline Myopathy cases. These symptoms include, 
early onset tremors of the jaw and lower limbs that subside shortly after birth, contracture 
of shoulder and hips, and a bowed out chest (van der Pol et al., 2014). Progressive muscle 
weakness and severe respiratory insufficiency result in neonatal death.  
 
A distinct pathological feature critical to the diagnosis of all Nemaline Myopathy 
cases is the presence of nemaline bodies in muscle biopsies. These bodies are rod-shaped 
accumulations of proteins that appear deep purple with Gomori trichrome staining in 
muscle biopsies (Figure 1). Antibody staining has shown that rods contain actin, alpha-
actinin, and nebulin, proteins important in muscle structure (Wallgren-Pettersson et al., 
1995); (Gurgel-Giannetti et al., 2001). 
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Figure 1: Gomori trichrome staining of muscle biopsy sections. Examples of nemaline bodies indicated 
by arrows. (Ilkovski et al., 2001)  
 
Normal Muscle Structure 
Skeletal muscle is composed of bundles of muscles cells called myofibers. These 
myofibers contain bundles of smaller filaments that arrange to form repeating contractile 
units called sarcomeres. Sarcomeres are made up of parallel thick and thin filaments. 
Interactions between these filaments generate muscle tension and contraction of skeletal 
muscles. The thick filaments are made of myosin and are attached to the Z-disk through 
the large, elastic protein titin. The thin filaments are composed mostly of actin, but also 
contain the proteins nebulin, troponin, tropomyosin, and cofilin (Figure 2). The end of the 
actin filament is anchored to the Z-disk through alpha-actinin. During muscle contraction, 
cross-bridges form between thin actin filaments and thick filament myosin heads. 
	  6 
Conformational changes in the myosin head causes the thin and thick filaments to slide 
past each other. The Z disk forms the border of each sarcomere and acts as an anchor for 
the thin filaments so that during muscle contraction the Z-disks are pulled closer together, 
resulting in muscle shortening (Lodish et al., 2000). All these proteins are important for 
proper organization and function of the thin filament within muscle and mutations in 
genes for these proteins have been linked to Nemaline Myopathy.  
 
 
Figure 2: Muscle Fiber Structure and Filament Arrangement. Overview of the arrangement of 
filaments in the muscle. The thick filaments are made of myosin and are attached to the Z-disk through titin. The 
thin filaments are composed mostly of actin, but also contain the proteins nebulin, troponin, tropomyosin, and cofilin. 
(Rahimov & Kunkel, 2013) 
 
Nemaline Myopathy Genetics 
The genetics of Nemaline Myopathy have been well studied in recent years and 
mutations in ten genes have been linked to Nemaline Myopathy in human patients. These 
genes code for alpha-skeletal muscle actin (ACTA1) (Nowak et al., 1999), slow alpha-
tropomyosin (TPM3) (Laing et al., 1995), nebulin (NEB) (Pelin et al., 1999) slow 
troponin T (TNNT1) (van der Pol et al., 2014), beta-tropomyosin (TPM2) (Marttila et al., 
2014), muscle- specific cofilin (CFL2) (Agrawal et al., 2007), leiomodin 3 (LMOD3) 
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(Yuen et al., 2014), Kelch protein family members KLHL40 (Ravenscroft et al., 2013), 
KLHL41 (Gupta et al., 2013), and KBTBD13 (Sambuughin et al., 2010). Frequency of 
occurrence, mode of inheritance, and phenotype severity varies among the different 
mutations (Table 1).  
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Table 1. Genes linked to Nemaline Myopathy. Mutations in ten different genes have been linked to 
nemaline myopathy in human patients. Proportion of Nemaline Myopathy cases data from North et al., 
2014. 
Gene Protein Mode of 
Inheritance 
Phenotype Proportion of 
Nemaline 
Myopathy 
NEB Nebulin Autosomal 
Recessive 
(AR) 
typical 
congenital 
50%  
ACTA1 Actin Autosomal 
Dominant 
(AD), AR 
severe 
congenital to 
childhood onset 
15-25% 
KLHL40 Kelch-like family 
member 40 
AR severe 
congenital 
5% 
TPM2 Tropomyosin, 
beta 
AD typical 
congenital 
2% 
TPM3 Tropomyosin, 
alpha slow 
AD, AR severe 
congenital, 
intermediate 
congenital, 
childhood onset 
2% 
KBTB13 Kelch repeat and 
BTB domain 
containing 
protein 
AD childhood onset Rare 
TNNT1 Troponin T, slow AR Amish Rare 
KLHL41 Kelch-like family 
member 41 
AR severe 
congenital, 
intermediate 
congenital, 
typical 
congenital 
Rare 
CFL2 Cofilin-2 AR typical 
congenital 
Rare 
LMOD3 Leiomodin 3 AR severe 
congenital 
Rare 
 
The majority of these genes are for structural proteins in the muscle, specifically 
those in the thin actin filament. And the same proteins that have been found to 
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accumulate in nemaline bodies in muscles of patients (actin and nebulin), contribute to 
75% of nemaline myopathy cases with known genetic causes. Mutations in the gene for 
the protein nebulin account for 50% of cases alone (North et al., 2014). 
 
Nebulin 
Nebulin is a very large protein (600-900kDa) that is highly expressed in muscle. 
Nebulin is a filament protein that runs alongside the thin actin filament with the C 
terminus anchored at the Z-line and the N terminus reaching out near the end of the thin 
filament. Although very large, most of nebulin is composed of approximately 185 small 
repeats of the same 35 amino acids. These small repeating units have been shown to 
function as actin-binding sites, suggesting that nebulin acts as a scaffold for actin and 
contributes to actin stability and function in the muscle (Wang et al., 1996). Studies show 
that nebulin is necessary for proper assembly and length in the thin filament of muscle. 
Nebulin knockout mice show reduced control of thin filament length and overall shorter 
thin filaments compared to wild type mice. Capping proteins which function to stop 
filament growth were also reduced in Nebulin knockout mice (Witt et al., 2006). Given 
that nebulin binds to actin and interacts with capping proteins, it is believed that nebulin 
regulates thin filament length through facilitating actin polymerization, promoting actin 
stability, and coordinating the termination of polymerization along with the capping 
proteins. Nebulin also plays a role in other structural aspects of muscle. Nebulin knockout 
mice show variations in Z-disc width and an accumulation of Z-disc proteins. Yeast two-
hybrid screens show a direct interaction between nebulin and Titin, a protein important to 
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Z-disc assembly (Witt et al., 2006). The accumulations of Z-disc protein in Nebulin 
knockout mice are very similar to nemaline bodies found in human Nemaline Myopathy 
patients. Recent studies have also shown that nebulin has important non-structural 
functions in muscle. 
During muscle contraction myosin heads on the thick filament interact with 
specific binding sites on the actin filament forming a bridge between the two filaments. 
Conformational changes in this bridge generate force and the filaments slide past each 
other resulting in muscle contraction. Nebulin has been shown to play a role in this 
critical interaction between myosin and actin. Nebulin knockout mice had a decrease in 
the number of strong actin-myosin interactions and thus a decrease in the ability to 
generate force (Bang et al., 2009).  
Muscle contraction is stimulated by an increase in cytosolic calcium that is 
released from the sarcoplasmic reticulum. Muscle relaxation occurs with reuptake of this 
calcium back into the sarcoplasmic reticulum. Regulation of calcium levels in the muscle 
is very important for proper muscle function and there is evidence that nebulin plays a 
role in calcium homeostasis in muscle cells. Nebulin knockout mice have an increase in 
sarcolipin, an inhibitor of sarcoplasmic reticulum calcium pumps. Calcium reuptake by 
the sarcoplasmic reticulum was found to be much slower in Nebulin knockout mice 
compared to wild type mice which also slowed muscle relaxation time in knockout mice 
(Ottenheijm et al., 2008). 
Nebulin is very important for the proper assembly and organization of muscle 
filaments and is involved in pathways critical to normal muscle function. Animal models 
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of nebulin knockdown have a very similar phenotype to human patients with Nemaline 
Myopathy with profound muscle weakness and the formation of nemaline bodies. 
Although nebulin would appear to be an excellent target for treatment for Nemaline 
Myopathy, structural proteins are hard to target with specific therapies. Recent discovery 
of mutations in non-filament genes suggest that Nemaline Myopathy may not be a 
disease caused solely by filament disorganization but that there may be alternative 
pathways that lead to disease. These pathways would also be easier to target for 
treatment. One such gene of interest is KLHL41. 
 
KLHL41  
Whole genome sequencing and Sanger sequencing of unrelated Nemaline 
Myopathy patients found mutations in KLHL41 linked to the development of Nemaline 
Myopathy. Two types of mutations were found and there was a clear phenotype-genotype 
correlation in patients. Patients with frameshift mutations had severe phenotypes and died 
at birth. Patients with missense mutations showed symptoms of the intermediate or 
typical congenital forms of Nemaline Myopathy and survived into late childhood or early 
adulthood (Gupta et al., 2013). 
Mutations in KLHL41 as a cause of Nemaline Myopathy have been confirmed in 
a zebrafish model. Knockdown of klhl41 in zebrafish resulted in leaner bodies and 
disorganized sarcomeric structure in comparison to normal zebrafish. Whole mount 
staining of actin filaments showed extensive muscle disorganization in klhl41mutant fish 
and ultrastructural evaluation by electron miscroscopy showed extensive sarcomeric 
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disorganization and presence of nemaline bodies in knockdown fish (Gupta et al., 2013). 
All of this is similar to the pathology seen in human patients with Nemaline Myopathy.  
KLHL41, also known as KBTBD10, Sarcosin, and Krp1, belongs to the Kelch repeat 
superfamily of proteins. Kelch family proteins are involved in many cell processes 
including, cytoskeleton arrangement, cell migration, protein degradation, and gene 
expression (Gupta & Beggs, 2014). KLHL41 is further grouped into the KLHL 
subfamily, the group of Kelch repeat proteins that contain an N-terminal BTB domain, a 
BACK domain, and C-terminal Kelch motifs (Figure 3) (Stogios & Privé, 2004). The role 
of the BTB domain is in promoting self-oligomerization and the function of the BACK 
domain is not fully known (Zipper & Mulcahy, 2002). The Kelch repeat domain contains 
five to seven repeats of distinct amino acid motifs and it is through these repeat domains 
that Kelch proteins can bind to specific substrates (Adams, Kelso, & Cooley, 2000).  
 
 
 
Figure 3: Domain Structure of Kelch Subfamily KLHL. (Gupta & Beggs, 2014) 
 
 KLHL41 is a protein that is only expressed in striated muscle but is also involved 
in a number of cellular pathways (Taylor et al., 1998). KLHL41 is highly expressed in 
myoblast cells and plays a role in muscle cell differentiation. Knockdown of KLHL41 in 
Homodimerization Protein-protein interactions 
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myoblast cells inhibits late phase differentiation (Du Puy et al., 2012). KLHL41 also 
plays a role in protein turnover in muscle through the ubiquitin-proteasome pathway. In 
order for old or damaged proteins to be degraded by the proteasome they first must be 
tagged with ubiquitin. Ubiquitination is a multistep process that begins with the E1 
ubiquitin activating enzyme transferring ubiquitin to the E2 ubiquitin conjugating 
enzyme. A third enzyme, E3 ubiquitin protein ligase, then completes the process by 
attaching the ubiquitin to the target protein. There are hundreds of different E3 ligases in 
eukaryotes but one subgroup, the Cullin-RING ligases, is of special interest in the study 
of Nemaline Myopathy. The Cullin-RING ligases are composed of three domains, a 
cullin protein, a RING protein, and a substrate adapter protein. The RING protein is the 
docking site for the E2 ubiquitin conjugating enzyme. The substrate adapter proteins bind 
to specific protein substrates allowing the Cullin-RING ligases to recognize a diverse 
number of proteins. The cullin protein acts as a scaffold for the final step of 
ubiquitination (Petroski & Deshaies, 2005). There are seven different cullin proteins in 
human cells and cullin 3 (CUL3) has been found to specifically interact with the BTB 
domain found in Kelch proteins (Canning et al., 2013). Kelch proteins function as the 
substrate specific adapters for CUL3 in the E3 ligase complex (Figure 4).  
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Figure 4: KLHL41 as a substrate adaptor for the E3-ubiquitin protein complex. Cul3 binds to the 
BTB domain of KLHL41 and substrates bind to through the Kelch repeat domains of KLHL41. Ubiquitin is 
transferred from E2 to the target substrates. Proteins tagged with ubiquitin are recognized and degraded by 
the proteasome. (Gupta & Beggs, 2014) 
 
There is also evidence that KLHL41 may play a role in another aspect of the 
proteasome pathway through interactions with the proteasome maturation protein 
(POMP) (Blandin et al., 2013). POMP is a molecular chaperone that facilitates the 
formation of the 20S proteasome subunit. The 20S subunit is the proteolytic component 
of the fully formed and active 26S proteasome (Fricke et al., 2007). Preliminary research 
shows that proteasomes are down regulated in Nemaline Myopathy patients regardless of 
gene mutation. Proteasome subunits also appear to form aggregates in muscle 
(unpublished data, Gupta Lab).  
KLHL41 has also been found to interact with a number of skeletal muscle 
proteins. Similar yeast two-hybrid screens have shown that KLHL41 interacts with 
nebulin and nebulin-related anchoring protein (NRAP) (Blandin et al., 2013), 
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(unpublished data) (Figure 5). Mutations in NEB cause 50% of genetically diagnosed 
Nemaline Myopathy cases. The consequences of the interaction of KLHL41 and nebulin 
have yet to be characterized; however, a recent study showed that the Kelch family 
protein KLHL40, which is highly similar to KLHL41, promotes stability of nebulin in 
vitro (Garg et al., 2014). 
 
 
Figure 5: Domains of Nebulin and NRAP that were found to interact with KLHL41. There is no 
preference for a specific domain and KLHL41 interacts with multiple features of the nebulin. (unpublished, 
Gupta Lab) 
 
Nemaline Myopathy is a clinically heterogeneous disease and although many 
genes have been linked to the disease in human patients, little is known about the 
pathological processes in Nemaline Myopathy. There is no specific therapy for treatment 
of Nemaline Myopathy and a great deal is still unknown about the biological functions of 
the proteins implicated in Nemaline Myopathy. The recent discovery of mutations in 
Kelch proteins and specifically, KLHL41, as a cause of disease in human patients provide 
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new pathways in which to study the mechanism of disease in Nemaline Myopathy. 
Understanding the role of KLHL41 in the development of Nemaline Myopathy is an 
important step in creating targeted therapies for Nemaline Myopathy. 	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Specific Aims 
The objective of the present study is to understand the significance of KLHL41-protein 
interactions on disease pathology in Nemaline Myopathy. Specifically: 
• Confirm KLHL41interactions with proteins identified by yeast two hybrid screens 
and Homogeneous Time Resolved Fluorescence (HTRF) studies in C2C12 cells. 
We will focus on the proteins POMP and nebulin. KLHL41 and POMP or NEB 
will be transfected in C2C12 cells and co-immunoprecipitation will be evaluated 
by Western blot.  
• We will test the effect of KLHL41 on stability of interactor proteins POMP and 
nebulin. POMP or NEB will be co-transfected with different amounts of KLHL41 
in C2C12 cells. Western blot analysis will be performed to quantify expression of 
interactor proteins. 
• Characterization of Klhl41 knockout C2C12 cell lines to develop assays for high-
throughput screening of small molecules. To confirm the knockout, Western blot 
analysis will be performed to identify KLHL41 expression levels in knockout cell 
lines. 
 
These studies will help identify the role of KLHL41 in the pathophysiology of 
Nemaline Myopathy and identify cellular pathways regulated by KLHL41 that can be 
used for targeted therapeutic development in Nemaline Myopathy. 	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METHODS 
Creating expression plasmids:  
NEBN-GFP 
 Nebulin fragment NEBN was prepared by amplifying N-terminal 1.2kb fragment 
of human NEB. RT-PCR of control human skeletal muscle tissue was performed to 
synthesize cDNA. cDNA transcript was amplified using primers 5’-GGGGACAAGTTT 
GTACAAAAAAGCAGGCTYYATGGCAGATGACGAAGACTATG-3” and 5’-GGGG 
ACCACTTTGTACAAGAAAGCTGGGTYTGTCTTATCTGGATGGACTTTGTAG-3’. 
Then the PCR product was incorporated into bacterial plasmid pDONR221 (Invitrogen, 
CA) through the Gateway Cloning Protocol BP recombination reaction (Thermo 
Scientific, NC) to create an entry clone. The new entry clone was transformed into Top10 
competent E.coli cells. After transformation, DNA from select colonies was isolated 
through mini prep (Qiagen, CA) and the NEBN sequence was confirmed through Sanger 
sequencing. Positive NEBN clone was introduced into destination vector pcDNA-
DEST47 (Invitrogen, CA) containing a GFP tag through the Gateway Cloning Protocol 
LR recombination reaction (Thermo Scientific, NC). The destination vector was 
transformed into Top10 competent E.coli cells and DNA from select colonies was 
isolated through mini prep (Qiagen, CA). NEBN sequence was confirmed through Sanger 
sequencing and positive clones were transformed into DH5α cells. DNA was amplified 
through maxi pep (Qiagen, CA) and NEBN sequence was confirmed through Sanger 
sequencing. DNA from maxi prep was used in transfection. 
 
	  19 
POMP-GFP 
 The full length human POMP cDNA was obtained from the PlasmID Repository 
at Harvard Medical School, clone ID HsCD00376430. Full length POMP cDNA was 
already incorporated into the pDONR221 bacterial plasmid. POMP was introduced into 
destination vector pcDNA-DEST47 (Invitrogen, CA) containing a GFP tag through the 
Gateway Cloning Protocol LR recombination reaction (Thermo Scientific, NC). The 
destination vector was transformed into Top10 competent E.coli cells and DNA from 
select colonies was isolated through mini prep (Qiagen, CA). POMP sequence was 
confirmed through Sanger sequencing and positive clones were transformed into DH5α 
cells. DNA was amplified through maxi prep (Qiagen, CA) and POMP sequence was 
confirmed through Sanger sequencing. DNA from maxi prep was used in transfection. 
 
KLHL41-nV5 
The full length human KLHL41 cDNA was obtained from the PlasmID 
Repository at Harvard Medical School, clone ID HsCD00076222. KLHL41 cDNA was 
already incorporated into the pDONR221 bacterial plasmid. KLHL41 was introduced into 
destination vector pcDNA3.1/nV5-Dest (Invitrogen, CA), containing a V5 epitope tag on 
the N terminal, through the Gateway Cloning Protocol LR recombination reaction 
(Thermo Scientific, NC). The destination vector was transformed into Top10 competent 
E.coli cells and DNA from select colonies was isolated through mini prep (Qiagen, CA). 
KLHL41 sequence was confirmed through Sanger sequencing and positive clones were 
transformed into DH5α cells. DNA was amplified through maxi prep (Qiagen, CA) and 
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KLHL41 sequence was confirmed through Sanger sequencing. DNA from maxi prep was 
used in transfection. 
 
Cell Culture: 
 C2C12 cells are skeletal muscle derived mouse myoblast cells.  The C2C12 cells 
were cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM), containing 
L-Glutamine, 110mg/L Sodium Pyruvate, and phenol red. DMEM was supplemented 
with 20% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 µg/ml streptomycin 
(PSG). All cells were grown at 37°C in a humidified incubator with 5% CO2. 
 
Transfection: 
C2C12 cells were plated in 6-well plates at a density of 2.0 x 105 cells in DMEM 
(20% FBS and 1% PSG) and incubated overnight at 37°C and 5% CO2 in humidity. Cells 
were then transfected using lipofectamine 2000 transfection agent (Life Technologies, 
NY) and desired concentrations of plasmids as listed in Tables 2-5. Cells were transfected 
for 4 hours and then transfection agents washed off with 2mL of DMEM (20% FBS). 
After washing, 2 mL of fresh DMEM (20% FBS) was added to each well and cells were 
incubated for 48hrs at 37°C and 5% CO2 in humidity. Cell lysates from the transfection 
were analyzed by Western blot analysis. 
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Table 2. Conditions for Co-transfection of POMP and KLHL41 
Plasmid Control 
(µg) 
KLHL41 
(µg)  
POMP 
(µg) 
KLHL41 
+POMP 
(µg) 
KLHL41 
+POMP 
(µg) 
KLHL41 
+POMP 
(µg) 
KLHL41-nV5 0 1 0 0.25 0.5 1 
POMP-GFP 0 0 2.5 2 2 2 
pCMV-Tag2 
(Empty) 
0 1.5 0 0 0 0 
 
 
 
Table 3. Conditions for transfection of POMP and KLHL41 for Immunoprecipitation  
 
Plasmid Control (µg) KLHL41 
(µg)  
POMP 
(µg) 
KLHL41 
+POMP 
(µg) 
KLHL41-nV5 0 2.5 0 1.0 
POMP-GFP 0 0 2.5 2.0 
 
 
 
Table 4. Conditions for Co-transfection of NEBN and KLHL41 
 
Plasmid Control 
(µg) 
KLHL41 
(µg) 
NEBN 
(µg) 
KLHL41 
+NEBN 
(µg) 
KLHL41 
+NEBN 
(µg) 
KLHL41 
+NEBN 
(µg) 
KLHL41-nV5 0 1 0 0.25 0.5 1.0 
NEBN-GFP 0 0 2 2 2 2 
pCMV-Tag2 
(Empty) 
0 1.5 0 0 0 0 
 
 
Table 5. Conditions for transfection of NEBN and KLHL41 for Immunoprecipitation  
 
Plasmid Control (µg) KLHL41 
(µg) 
NEBN 
(µg) 
KLHL41 
+NEBN 
(µg) 
KLHL41-nV5 0 2.5 0 1.0 
NEBN-GFP 0 0 2.5 2.0 
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Cell Lysis: 
Media was removed and 6-well plates were placed on ice. One protease inhibitor 
tablet (Sigma Aldrich, PA) was added to 5mL cold Radio immunoprecipitation 
assay buffer (RIPA) (VWR International, NJ). 75µL of RIPA buffer with protease 
inhibitor was added to each well. Cells were kept on ice for five minutes and plate was 
swirled occasionally to ensure uniform spreading and scraped to collect cell lysate. Cell 
lysate was then transferred to a microcentrifuge tube and centrifuged at 13,000 rpm for 
15 minutes at 4°C. The supernatant was transferred to a new tube and stored at -80°C for 
further analysis. 
 
BCA Protein Assay: 
The protein concentration of each sample to be used in western blot was 
standardized using a BCA Protein Assay kit (Thermo Scientific, CA). Bovine Serum 
Albumin (BSA) was used to create a standard reference curve to determine the 
concentrations in the unknown samples.  Samples were diluted to 2000, 1500, 1000, 750, 
500, 250, 125, 25 and 0 µg/mL concentrations according to the kit instructions. 10µL of 
standard samples and 2µL of unknown sample (diluted with 8µL nuclease free H2O) were 
used for protein concentration quantification. 200 µL of working BCA reagent was added 
to each sample and incubated at 37°C for 30 minutes. Absorbance was measured at 
562nm using a Nanodrop 1000 spectrophotometer. The concentration of protein in 
unknown samples was calculated using the standard curve created from the BSA standard 
samples.  
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Western Blot: 
100µg-200µg of protein samples were analyzed by western blot. 10 µL Bolt LDS 
sample buffer 4X and 4µL Bolt reducing agent 10X (Life Technologies, NY) were added 
to each sample. RIPA buffer was added to make the final volume to 40 µL. Samples were 
heated at 95°C for 10 minutes. Running buffer was prepared by diluting 20 mL of 20X 
Bolt MES SDS Running Buffer (Life Technologies, NY) with 380 mL of deionized 
water. Novex Bolt 4-12% Bis-Tris Plus 10 well gels were used in a Thermo Fisher 
Scientific Mini Gel Tank (Thermo Scientific, NC). Each well of the gel was loaded with 
40µL of sample. 15µL of SeeBlue Plus2 Pre-stained Protein Standard (Life Technologies, 
NY) was loaded as the protein size marker.  Electrophoresis was carried out using a 
BioRad PowerPac Basic Power Supply at 180v for 75 minutes (till 38kDa band of the 
standard ladder migrated to the bottom of the gel) The proteins separated by molecular 
weight were transferred to an Immun-Blot PVDF membrane (pore size 0.2µm) (Biorad, 
CA) using a mini blot module, wet transfer system (Life Technologies, NY) in transfer 
buffer (50mL 20X Bolt Transfer Buffer (Life Technologies, NY), 100mL methanol, and 
850mL diH2O). The transfer was carried out at 30 V for 90 minutes at 4°C.  
Following the transfer, the membrane was blocked in blocking buffer solution of 
5% milk in 1x Tris Buffered Saline (Boston Bioproducts, MA) with 0.1% Tween 20 
(Sigma Aldrich, PA) (TBST) on an orbital shaker at room temperature for 1 hour. For 
Western blot analysis the following antibodies were used: Anti-GFP (Abcam, MA), V5 
Epitope Tag Antibody (Life Technologies, NY), Anti-GAPDH (Abcam, MA), Goat Anti-
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Mouse IgG (HL)-HRP (Biorad, CA), and Goat Anti-Rabbit IgG (HL)-HRP (Biorad, CA). 
Dilutions used in western blot analysis are listed below in Table 6.  
 
Table 6. Antibodies and the associated dilutions used for Western blot 
 
Primary Antibody Dilution Secondary Antibody Dilution 
Anti-GFP 1:1000 Anti-Rabbit IgG HRP 1:5000 
V5 antibody 1:2000 Anti-Mouse IgG HRP 1:5000 
Anti-GAPDH 1:1000 Anti-Mouse IgG HRP 1:7500 
 
Primary antibodies were diluted in blocking buffer. The membrane was incubated 
with the primary antibody overnight, at 4°C on a shaker. Membrane was washed twice 
for 15 minutes each in TBST on an orbital shaker. The membrane was then incubated 
with the desired secondary antibody for one hour, at room temperature on a shaker. 
Secondary antibodies were also diluted in blocking buffer. The membrane was washed 
twice for 15 minutes each in TBST on an orbital shaker. Membrane was developed with 
3mL of developing solution, SuperSignal™ West Pico Chemiluminescent Substrate 
(Thermo Scientific, NC) for 5 minutes and developed with an x-ray film with a KODAK 
X-OMAT machine. 
 To reprobe the same membrane, the membrane was washed in TBST and stripped 
in Restore™ Western Blot Stripping Buffer (Thermo Scientific, NC) for 30 minutes at 
room temperature on a shaker. The membrane was then washed in TBST and blocked for 
the second antibody or wrapped in a plastic wrap and stored at -20°C. 
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Quantifying Western Blot Band Intensity 
 Relative density of Western blot bands was measured using ImageJ. Band 
densities of proteins of interest were normalized against GAPDH in the control condition 
of each experiment.  
 
Immunoprecipitation: 
Cell extracts were prepared as described earlier for Western blot analysis. 50µL-
100µL of Anti-V5 Agarose Affinity Gel (Sigma Aldrich, PA) was washed five times with 
1X PBS. Cell lysate was added to the settled V5-resin according to Tables 7 and 8 below. 
Tubes with resin and cell lysate were incubated for 2-3 hours on an orbital shaker at 4°C. 
After incubation, the resin was washed four times with RIPA buffer. After the final wash, 
50µL of 2X Bolt LDS sample buffer (Life Technologies, NY) was added to each tube to 
elute the immunoprecipitated proteins. Tubes were incubated at 100°C for 5 minutes, 
supernatant was collected and stored at -80°C for Western blot analysis.  
 
Table 7. Conditions for NEBN and KLHLL41 Immunoprecipitation 
 
 
  
 
  
 
 
 
 
 
 
 V5 Agarose Cell Lysate 
Control 50µL 175µL 
KLHL41 only 50µL 175µL 
KLHL41 + NEBN 100µL 375µL 
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Table 8. Conditions for POMP and KLHLL41 Immunoprecipitation 
 
 
 
 
Characterizing Klhl41 knockdown cells 
 CRISPR technology was used to create KLHL41 knockout C2C12 cells 
(unpublished data, Gupta Lab). Two different sgRNA were created to target exon 1 of 
mouse Klhl41, resulting in 11 distinct clones. Klhl41 targeted C2C12 cells were grown in 
cell culture conditions described above. Western blot analysis was used to identify clones 
with lower expression of KLHL41 in comparison to controls. Western blot membrane 
was probed with primary antibody Anti-KBTBD10 (AB1) (Sigma Aldrich, PA) at a 
concentration of 1:250 and secondary antibody Anti-Rabbit IgG HRP (Biorad, CA) at a 
concentration of 1:5000. Antibodies were diluted in blocking buffer (5% milk in 1X 
TBST). Normal C2C12 cells were used as a control for endogenous KLHL41 levels.  
 
 
 V5 Agarose Cell Lysate 
Control 50µL 150µL 
KLHL41 only 50µL 150µL 
KLHL41 + POMP 100µL 200µL 
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RESULTS 
The effect of KLHL41 on the stability of interactor protein POMP was 
investigated by overexpression studies in C2C12 cells. Cells were co-transfected with 
different amounts of KLHL41-nV5 and constant concentrations of POMP-GFP. Protein 
expression was confirmed by Western blot analysis and protein levels were compared by 
measuring relative band intensity on Western blot. When co-transfected with KLHL41-
nV5, POMP protein levels were reduced compared to transfection of POMP-GFP alone. 
POMP level was decreased by 32% when co-transfected with 0.25µg of KLHL41-nV5, by 
69% with 0.5µg of KLHL41-nV5, and by 73% with 1.0µg of KLHL41-nV5 (Figure 6). 
This suggests that KLHL41 is a negative regulator of POMP in myoblasts. 
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Figure 6: C2C12 Transfection with Overexpression of POMP-GFP and KLHL41nV5 A) Western blot 
analysis of proteins. Different conditions and antibodies used are labeled. 
 
 
 
 
 
 
KLHL41-nV5 68kDa 
POMP-­‐GFP	  42kDa	  
GAPDH	  36kDa	  
C
on
tro
l 
K
LH
L4
1 
PO
M
P 
K
LH
L4
1 
0.
25
μg + PO
M
P 
K
LH
L4
1 
0.
5μg + P
O
M
P 
K
LH
L4
1 
1.
0μg + P
O
M
P 
	  29 
 
 
Figure 6: C2C12 Transfection with Overexpression of POMP-GFP and KLHL41nV5 B) 
Quantification of POMP protein levels was performed by imageJ and normalized with GAPDH levels. 
 
 
The effect of KLHL41 on the stability of interactor protein NEB was investigated 
by overexpression studies in C2C12 cells. Cells were co-transfected with different 
amounts of KLHL41-nV5 and constant concentrations of NEBN-GFP. Protein expression 
was confirmed by Western blot analysis. Preliminary results suggest that when co-
transfected with KLHL41-nV5, NEB protein levels are reduced compared to transfection 
of NEB-GFP alone (Figure 7). However, this result needs to be confirmed on a single 
Western blot.  
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Figure 7: C2C12 Transfection with Overexpression of NEBN-GFP and KLHL41nV5. Western blot 
analysis of proteins. Different conditions and antibodies used are labeled. Note: NEBN and KLHL41 
images taken from two separate Western blots. 
 
 
In order to investigate an interaction between KLHL41 and POMP or nebulin, 
immunoprecipitation (IP) was performed. Using cell lysates co-expressing KLHL41-nV5 
and POMP-GFP or NEBN-GFP, the IP was performed using anti-V5 antibody followed 
by Western blot analysis. Both POMP and NEBN were not found to be associated with 
KLHL41 contrary to previous studies (Spence et al., 2006); (Blandin et al., 2013). One 
potential reason could be the high levels of detergents in RIPA buffer used in this 
experiment that may have disrupted the interactions between KLHL41 and POMP or 
NEBN. Figure 8 shows IP results with KLHL41 and POMP. Figure 9 shows IP results 
with KLHL41 and NEBN. 
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Figure 8: Anti-V5 Immunoprecipitation with co-transfection of KLHL41-nV5 and POMP-GFP. 
Western blot analysis of proteins. Different conditions and antibodies used are labeled. POMP-GFP is 
present in the input lane but does not appear in the IP lane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Anti-V5 Immunoprecipitation with co-transfection of KLHL41-nV5 and NEBN-GFP. 
Western blot analysis of proteins. Different conditions and antibodies used are labeled. NEBN-GFP is 
present in the input lane but does not appear in the IP lane. 
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Klhl41 knockout C2C12 cells were previously created using CRISPR technology. 
Studies have shown that knockdown of KLHL41 inhibits differentiation in C2C12 cells 
(Du Puy et al., 2012). The first step in characterizing our Klhl41 knockdown cell line was 
to identify clones that showed low levels of KLHL41 in comparison to control by 
Western blot analysis (Figure 10). Cell lines A, B, F, G, H, and I were found to have low 
KLHL41 expression, indicating successful knockdown of Klhl41. 
 
 
 
Figure 10: Western blot analysis of KLHL41 levels in Klhl41 knockout C2C12 cells. Western blot 
probed with Anti-KBTBD10. 	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DISCUSSION 
 
 Although Nemaline Myopathy is a relatively rare genetic disorder, the severity of 
symptoms makes it a devastating disease to patients and their families. Even though the 
genetics of Nemaline Myopathy has been well studied in recent years and multiple genes 
have been linked to Nemaline Myopathy in human patients there are no effective, specific 
therapies for inherited Nemaline Myopathy. Mutations in genes for thin filament proteins 
are responsible for 75% of cases with a known genetic diagnosis; however, structural 
proteins do not make good targets for specific therapies. For this reason, recent gene 
discovery of Kelch family proteins involved in Nemaline Myopathy provides a promising 
new target for therapeutic development. Nemaline Myopathy is a disease of abnormal 
protein accumulation and Kelch proteins interact with CUL3 in the ubiquitin-proteasome 
pathway. Therefore, studying the role of Kelch proteins in muscle protein turnover could 
provide great insight into the mechanism of disease and future therapeutic strategies. 
Gupta Lab has previously identified that KLHL41 interacts with proteins involved in the 
proteasome pathway as well as structural muscle proteins (unpublished data, Gupta Lab). 
This current study sought to characterize these interactions. 
 Co-transfection of POMP and varying amounts of KLHL41 helped characterize 
the relationship between these two proteins. Western blot analysis shows lower levels of 
POMP with increasing amounts of KLHL41. It is believed that KLHL41 acts as a 
substrate specific adapter for the E3 ligase in the ubiquitin-proteasome pathway and our 
data suggests that POMP may be one of these substrates that KLHL41 helps target for 
degradation.  
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The relationship between KLHL41 and Nebulin still needs to be fully 
characterized but co-transfection of KLHL41 and NEBN has shown preliminary evidence 
that there is a negative relationship between the two proteins. Western blot analysis 
showed lower levels of Nebulin with increasing amounts of KLHL41; however these 
results have not been confirmed in a single Western blot. Work is ongoing to confirm 
these initial results. In order to further investigate these relationships, future experiments 
should quantify the ubiquitination levels of POMP and NEB proteins when co-transfected 
with KHLH41. This will help identify if POMP and NEB are some of the substrates 
KLHL41 recognizes as part of the E3 ligase complex.  
Co-transfection and immunoprecipitation of KLHL41 with POMP or NEB did not 
confirm the direct physical interaction that previous yeast two-hybrid screens had 
suggested. Considering the high amount of detergents in RIPA buffer that might have 
impacted the interactions between these proteins, future studies should be performed with 
different IP buffers to optimize the immunoprecipitation conditions.   
Similar co-transfection and immunoprecipitation studies were conducted by Garg 
et al (2014) to investigate the relationship between KLHL40 and nebulin. KLHL40 is 
another Kelch family protein that has been linked to Nemaline Myopathy and possesses 
Kelch repeat domains highly similar to KLHL41 (Gupta & Beggs, 2014). Garg et al 
(2014) identified NEB as a binding partner of KLHL40 through a yeast 2-hybrid screen 
and confirmed binding by coimmunoprecipitation. KLHL40 and NEB fragment were 
then co-expressed in COS7 cells, a fibroblast like cell, and KLHL40 dramatically 
increased protein levels of NEB by Western blot analysis. Although KLHL40 and 
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KLHL41 are highly similar our preliminary results show a negative relationship between 
KLHL41 and NEB, in contrast to Garg et al results showing a positive relationship 
between KLHL40 and NEB. It is possible that KLHL40 and KLHL41 both contain Kelch 
repeat domains that interact with NEB but the proteins perform opposite functions to 
balance protein turnover in the muscle. 
Western blot analysis showed knockout of Klhl41 in six of eleven lines of C2C12 
cells. Knockdown of Klhl41 in C2C12 cells has been previously shown to inhibit 
differentiation (Du Puy et al., 2012). Future studies will further characterize the knockout 
cell lines through differentiation and immunofluorescence assays. Characterization of 
Klhl41 knockdown C2C12 cell lines and identifying cellular phenotypes will be crucial 
for their use for high-throughput screening of small molecules to identify novel 
therapeutic compounds for Nemaline Myopathy. 
 This study could not re-confirm a direct physical interaction between KLHL41 
and POMP or NEB identified by Y2H and HTRF. However, co-transfection experiments 
showed that KLHL41 is a negative regulator of POMP and potentially nebulin in muscle 
cells. Future studies will help to understand the functional significance of this negative 
regulation. A greater understanding of the role of KLHL41 in the pathophysiology of 
Nemaline Myopathy is critical to development of future therapeutic strategies. 
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